Real-world Study of Dedifferentiated Liposarcoma Patients in China

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1390 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-13

Study Completion Date

2024-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will characterize patients with dedifferentiated liposarcoma (DDLPS) in China, including an understanding of demographic, and clinical characteristics as well as treatment patterns and clinical outcomes associated with the current real-world treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors

NCT05468970

Bone and Soft Tissue Tumors Clinical Features

RECRUITING

Prognostic Value of TIL in Nasopharyngeal Carcinoma

NCT06763640

Nasopharyngeal Carcinoma (NPC)

ENROLLING_BY_INVITATION

Identify Prognostic Biomarkers of Lung Cancer

NCT05010330

Lung Cancer Lung Adenocarcinoma Lung Squamous Cell Carcinoma +1 more

UNKNOWN

The Real Word Study of Albumin-binding Taxol for Lung Cancer Treatment

NCT03802409

Lung Cancer

UNKNOWN

Predictive Models of Treatment Responses and Survival Outcomes in Patients With Osteosarcoma

NCT05194605

Osteosarcoma

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dedifferentiated Liposarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DDLPS patients with 1L treatment at index date (Cohort 1)

Patients with unresectable locally advanced or metastatic differentiated liposarcoma (DDLPS) who received at least one line of systemic antineoplastic treatment by the end of cohort identification period (index date = start date of first line (1L) treatment).

No interventions assigned to this group

DDLPS patients without 1L treatment at index date (Cohort 2)

Patients with DDLPS who have not initiated 1L systemic antineoplastic treatment by the end of cohort identification period (index date = date of initial DDLPS diagnosis during cohort identification period). Patients who initiated 1L treatment afterwards or patients who received adjuvant and/or neoadjuvant therapy only through follow-up were included in Cohort 2.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient has two or more documented clinical visits in the National Anti-Tumor Drug Surveillance System (NATDSS) network on or after January 1, 2013.
* Patient has a confirmed diagnosis of dedifferentiated liposarcoma (DDLPS) during his/her lifetime.
* At least 18 years old at the date of initial diagnosis.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No